Ken Suzawa

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Charles M. Rudin, Marissa Mattar, Elisa de Stanchina, 2018, Clinical Cancer Research.

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E.

Shigemi Matsumoto, Takashi Ninomiya, Shuta Tomida, 2018, The oncologist.